Mirdametinib Represents Long-Awaited Approved Treatment Option for Adult NF1-Associated PNs
Justin T. Jordan, MD, MPH, FAAN, discusses the implications of the FDA approval of mirdametinib for adult NF1-associated plexiform neurofibromas.
Related Articles
Nuanced Biomarker Tests and Immunotherapy Strategies May Usher ASCO 2025 Data Into the Clinic
Oncology experts share topline insights from 19 of the most exciting abstracts from the 2025 ASCO Annual Meeting.
Cilta-Cel Data Set a High Bar for Anito-Cel in Relapsed/Refractory Myeloma
Darren Pan, MD, discusses updates regarding cilta-cel and anito-cel for the treatment of patients with relapsed/refractory multiple myeloma.
Data for Elotuzumab Support Further Investigation in JAK Inhibitor–Based Combinations in Myelofibrosis
Safety and efficacy data for elotuzumab support its further investigation in the treatment of myelofibrosis.
Lutetium Lu 177 Vipivotide Tetraxetan Positioned for Earlier Use in mCRPC While Radium-223 Sequencing Requires Further Clarification
Qian (Janie) Qin, MD, discusses the current arsenal of radioligand therapies in metastatic castration-resistant prostate cancer.
KIM-1 Represents a Potential Biomarker for Outcomes and Response in RCC
KIM-1 levels have shown the ability to predict therapeutic benefit in patients with renal cell carcinoma.
FDA Issues CRL for Glofitamab Plus Chemo in R/R DLBCL
The FDA issued a CRL to the application for glofitamab plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.
Luspatercept Plus Concomitant JAK Inhibitor Therapy Misses Primary End Point in Myelofibrosis-Associated Anemia
Luspatercept plus a concomitant JAK inhibitor didn’t meet the primary end point of 12-week RBC transfusion independence in myelofibrosis-associated anemia.
Investigational Neoantigen Vaccines Target RCC Mutations and Drive Durable T-Cell Activity
David A. Braun, MD, PhD, discusses findings from a study of personalized neoantigen vaccines in patients with high-risk, resectable ccRCC.
Novel CAR T-Cell Therapy Could Pave the Way for Improvements in Advanced ccRCC Management
Research supports the use of novel CAR T-cell therapy targeting CAIX and CD70 for the treatment of patients with advanced ccRCC.
FDA Grants Priority Review to TAR-200 for BCG-Unresponsive High-Risk NMIBC
The FDA has granted priority review to TAR-200 for BCG-unresponsive, high-risk NMIBC with CIS, with or without papillary tumors.